Inverness Medical Innovations
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of osteoporosis product maker Ostex in stock deal worth roughly $37 mil. rounds out the women's healthcare provider's intellectual property portfolio, firm says in Sept. 9 conference call. Inverness cites the Ostex NTx assay's increasing acceptance for management and monitoring of osteoporosis treatments as a primary driver of the deal...
You may also be interested in...
Inverness Builds Sales With Consumer Products, Acquires Apogent Unit
Inverness Medical Innovations expects its newly acquired Applied Biotech diagnostics business to add about $20 mil. to annual revenues
Inverness/Ostex International
Women's health firm completes merger with osteoporosis test maker Ostex. Under the deal, each share of Ostex was exchanged for 0.126 shares of Inverness (1"The Gray Sheet" Sept. 16, 2002, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.